ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a biotechnology company focusing on developing innovative therapies to treat neurodegenerative diseases. The company leverages its proprietary technology platform to identify and target misfolded proteins commonly associated with neurodegenerative conditions such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). ProMIS Neurosciences aims to address unmet medical needs by creating precision medicines that specifically target these destructive proteins, potentially altering the course of these debilitating diseases. Operating at the intersection of scientific research and therapeutic development, ProMIS plays a significant role in the biotech sector, especially within the broader pharmaceutical and healthcare industries. Through collaborations with academic institutions and key strategic partners, the company enhances its research capabilities and accelerates the development of its therapeutic candidates. Headquartered in Toronto, Canada, ProMIS Neurosciences Inc. stands as a crucial player in the race to develop effective treatments for neurodegenerative diseases, reflecting the growing importance of targeted therapies in the healthcare market.